1. Home
  2. CDNA vs EMBC Comparison

CDNA vs EMBC Comparison

Compare CDNA & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDNA
  • EMBC
  • Stock Information
  • Founded
  • CDNA 1998
  • EMBC 1924
  • Country
  • CDNA United States
  • EMBC United States
  • Employees
  • CDNA N/A
  • EMBC N/A
  • Industry
  • CDNA Medical Specialities
  • EMBC Medical/Dental Instruments
  • Sector
  • CDNA Health Care
  • EMBC Health Care
  • Exchange
  • CDNA Nasdaq
  • EMBC Nasdaq
  • Market Cap
  • CDNA 712.2M
  • EMBC 803.0M
  • IPO Year
  • CDNA 2014
  • EMBC N/A
  • Fundamental
  • Price
  • CDNA $18.03
  • EMBC $14.50
  • Analyst Decision
  • CDNA Buy
  • EMBC Buy
  • Analyst Count
  • CDNA 7
  • EMBC 2
  • Target Price
  • CDNA $26.00
  • EMBC $18.50
  • AVG Volume (30 Days)
  • CDNA 1.2M
  • EMBC 374.6K
  • Earning Date
  • CDNA 11-04-2025
  • EMBC 11-25-2025
  • Dividend Yield
  • CDNA N/A
  • EMBC 4.15%
  • EPS Growth
  • CDNA N/A
  • EMBC 18.26
  • EPS
  • CDNA 1.22
  • EMBC 1.42
  • Revenue
  • CDNA $357,998,000.00
  • EMBC $1,102,500,000.00
  • Revenue This Year
  • CDNA $12.73
  • EMBC N/A
  • Revenue Next Year
  • CDNA $11.90
  • EMBC N/A
  • P/E Ratio
  • CDNA $14.75
  • EMBC $10.18
  • Revenue Growth
  • CDNA 14.46
  • EMBC N/A
  • 52 Week Low
  • CDNA $10.96
  • EMBC $9.20
  • 52 Week High
  • CDNA $26.37
  • EMBC $21.48
  • Technical
  • Relative Strength Index (RSI)
  • CDNA 67.03
  • EMBC 56.37
  • Support Level
  • CDNA $15.60
  • EMBC $13.61
  • Resistance Level
  • CDNA $17.09
  • EMBC $14.81
  • Average True Range (ATR)
  • CDNA 1.02
  • EMBC 0.62
  • MACD
  • CDNA 0.15
  • EMBC 0.05
  • Stochastic Oscillator
  • CDNA 95.64
  • EMBC 75.16

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: